Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.
Immunosuppression regimens based on belatacept rather than cyclosporine are associated with better 7-year outcomes among kidney transplant recipients.
Patients who undergo radical prostatectomy (RP) have unrealistic expectations about their sexual function after the operation, new study findings reveal.
Treatment with recombinant human erythropoietin (rHuEPO) in patients with chronic kidney disease (CKD) but not on dialysis corrects anemia, reduces the need for blood transfusions, and improves quality of life and exercise capacity, researchers concluded from a systematic review.
Data support the use of enzalutamide instead of bicalutamide in patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC), researchers concluded.
Earlier treatment of anemia with an erythropoiesis-stimulating agent (ESA) may be more effective at decreasing the risk of renal events in patients with chronic kidney disease (CKD) not yet on dialysis.
Many small practices fall short on requirements because they do not have the resources to comply.
Many diagnostic tests for investigating acute kidney injury (AKI) have limited clinical utility, even when results are positive or abnormal, a new study found.
Men who regularly consume foods rich in flavonoids may have a lower risk of erectile dysfunction (ED).
A new online tool may help predict whether patients with chronic kidney disease will develop kidney failure in the next 2 to 5 years.
Appointment schedules should reflect physicians' work style and patient demands.
Increased clinical research has been focused on the sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the management of type 2 diabetes.
Access our job board to view over 1,000 job openings throughout the US.
Tell us about your social media habits for a chance to win a free gift card.
Access information and support materials for Xtandi that can help your practice and patients with metastatic castration-resistant prostate cancer.